

# Shixia Wang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10044954/publications.pdf>

Version: 2024-02-01

57  
papers

2,083  
citations

257450

24  
h-index

243625

44  
g-index

59  
all docs

59  
docs citations

59  
times ranked

3269  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of vaccine administration modality on immunogenicity and efficacy. <i>Expert Review of Vaccines</i> , 2015, 14, 1509-1523.	4.4	171
2	Follicular regulatory T cells repress cytokine production by follicular helper T cells and optimize IgG responses in mice. <i>European Journal of Immunology</i> , 2016, 46, 1152-1161.	2.9	131
3	Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. <i>Vaccine</i> , 2008, 26, 1098-1110.	3.8	103
4	The wide utility of rabbits as models of human diseases. <i>Experimental and Molecular Medicine</i> , 2018, 50, 1-10.	7.7	103
5	Polyvalent HIV-1 Env vaccine formulations delivered by the DNA priming plus protein boosting approach are effective in generating neutralizing antibodies against primary human immunodeficiency virus type 1 isolates from subtypes A, B, C, D and E. <i>Virology</i> , 2006, 350, 34-47.	2.4	98
6	Relative contributions of codon usage, promoter efficiency and leader sequence to the antigen expression and immunogenicity of HIV-1 Env DNA vaccine. <i>Vaccine</i> , 2006, 24, 4531-4540.	3.8	92
7	Cross-subtype antibody and cellular immune responses induced by a polyvalent DNA prime-protein boost HIV-1 vaccine in healthy human volunteers. <i>Vaccine</i> , 2008, 26, 3947-3957.	3.8	91
8	Enhanced Immunogenicity of gp120 Protein When Combined with Recombinant DNA Priming To Generate Antibodies That Neutralize the JR-FL Primary Isolate of Human Immunodeficiency Virus Type 1. <i>Journal of Virology</i> , 2005, 79, 7933-7937.	3.4	85
9	Heterologous HA DNA vaccine prime-inactivated influenza vaccine boost is more effective than using DNA or inactivated vaccine alone in eliciting antibody responses against H1 or H3 serotype influenza viruses. <i>Vaccine</i> , 2008, 26, 3626-3633.	3.8	85
10	Hemagglutinin (HA) Proteins from H1 and H3 Serotypes of Influenza A Viruses Require Different Antigen Designs for the Induction of Optimal Protective Antibody Responses as Studied by Codon-Optimized HA DNA Vaccines. <i>Journal of Virology</i> , 2006, 80, 11628-11637.	3.4	82
11	A DNA vaccine producing LcrV antigen in oligomers is effective in protecting mice from lethal mucosal challenge of plague. <i>Vaccine</i> , 2004, 22, 3348-3357.	3.8	80
12	Identification of Two Neutralizing Regions on the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Produced from the Mammalian Expression System. <i>Journal of Virology</i> , 2005, 79, 1906-1910.	3.4	75
13	A cGAS-Independent STING/IRF7 Pathway Mediates the Immunogenicity of DNA Vaccines. <i>Journal of Immunology</i> , 2016, 196, 310-316.	0.8	72
14	Concurrent Measurement of Dynamic Changes in Viral Load, Serum Enzymes, T Cell Subsets, and Cytokines in Patients with Severe Fever with Thrombocytopenia Syndrome. <i>PLoS ONE</i> , 2014, 9, e91679.	2.5	54
15	Identification of Aim2 as a Sensor for DNA Vaccines. <i>Journal of Immunology</i> , 2015, 194, 630-636.	0.8	47
16	Mathematic modeling of COVID-19 in the United States. <i>Emerging Microbes and Infections</i> , 2020, 9, 827-829.	6.5	46
17	DNA immunization as a technology platform for monoclonal antibody induction. <i>Emerging Microbes and Infections</i> , 2016, 5, 1-12.	6.5	45
18	Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits. <i>Journal of Virology</i> , 2016, 90, 11007-11019.	3.4	41

#	ARTICLE	IF	CITATIONS
19	A novel DNA and protein combination COVID-19 vaccine formulation provides full protection against SARS-CoV-2 in rhesus macaques. <i>Emerging Microbes and Infections</i> , 2021, 10, 342-355.	6.5	37
20	Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response. <i>Journal of Virology</i> , 2016, 90, 10993-11006.	3.4	33
21	Use of ELISpot assay to study HBs-specific B cell responses in vaccinated and HBV infected humans. <i>Emerging Microbes and Infections</i> , 2018, 7, 1-10.	6.5	30
22	Select gp120 V2 domain specific antibodies derived from HIV and SIV infection and vaccination inhibit gp120 binding to CD4. <i>PLoS Pathogens</i> , 2018, 14, e1007278.	4.7	29
23	Contribution of TLR4 and MyD88 for adjuvant monophosphoryl lipid A (MPLA) activity in a DNA prime-protein boost HIV-1 vaccine. <i>Vaccine</i> , 2014, 32, 5049-5056.	3.8	27
24	Structural Analysis of the Glycosylated Intact HIV-1 gp120-CD4 Antibody Complex Using Hydroxyl Radical Protein Footprinting. <i>Biochemistry</i> , 2017, 56, 957-970.	2.5	27
25	Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001. <i>Journal of Virology</i> , 2016, 90, 10362-10378.	3.4	26
26	Assays for the assessment of neutralizing antibody activities against Severe Acute Respiratory Syndrome (SARS) associated coronavirus (SCV). <i>Journal of Immunological Methods</i> , 2005, 301, 21-30.	1.4	25
27	Relative immunogenicity and protection potential of candidate <i>Yersinia Pestis</i> antigens against lethal mucosal plague challenge in Balb/C mice. <i>Vaccine</i> , 2008, 26, 1664-1674.	3.8	24
28	Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal <i>Yersinia pestis</i> challenge. <i>Vaccine</i> , 2011, 29, 6802-6809.	3.8	24
29	Delivery of DNA to Skin by Particle Bombardment. , 2004, 245, 185-196.		22
30	Profiles of Acute Cytokine and Antibody Responses in Patients Infected with Avian Influenza A H7N9. <i>PLoS ONE</i> , 2014, 9, e101788.	2.5	20
31	DNA Immunization for HIV Vaccine Development. <i>Vaccines</i> , 2014, 2, 138-159.	4.4	19
32	Application of area scaling analysis to identify natural killer cell and monocyte involvement in the GranToxiLux antibody dependent cell-mediated cytotoxicity assay. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 436-447.	1.5	18
33	High Neutralizing Antibody Levels Against Severe Acute Respiratory Syndrome Coronavirus 2 Omicron BA.1 and BA.2 After UB-612 Vaccine Booster. <i>Journal of Infectious Diseases</i> , 2022, 226, 1401-1406.	4.0	18
34	DNA Immunization. <i>Current Protocols in Microbiology</i> , 2013, 31, 18.3.1-18.3.24.	6.5	17
35	Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination. <i>Vaccine</i> , 2017, 35, 1464-1473.	3.8	15
36	Structural analysis of a novel rabbit monoclonal antibody R53 targeting an epitope in HIV-1 gp120 C4 region critical for receptor and co-receptor binding. <i>Emerging Microbes and Infections</i> , 2015, 4, 1-8.	6.5	14

#	ARTICLE	IF	CITATIONS
37	HIV-1 R5 Macrophage-Tropic Envelope Glycoprotein Trimers Bind CD4 with High Affinity, while the CD4 Binding Site on Non-macrophage-tropic, T-Tropic R5 Envelopes Is Occluded. <i>Journal of Virology</i> , 2018, 92, .	3.4	14
38	DNA vaccine prime followed by boost with live attenuated virus significantly improves antigen-specific T cell responses against human cytomegalovirus. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2120-2132.	3.3	13
39	Post-translational intracellular trafficking determines the type of immune response elicited by DNA vaccines expressing Gag antigen of Human Immunodeficiency Virus Type 1 (HIV-1). <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2095-2102.	3.3	12
40	Potent monoclonal antibodies against <i>Clostridium difficile</i> toxin A elicited by DNA immunization. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2157-2164.	3.3	12
41	Glycan Profiles of gp120 Protein Vaccines from Four Major HIV-1 Subtypes Produced from Different Host Cell Lines under Non-GMP or GMP Conditions. <i>Journal of Virology</i> , 2020, 94, .	3.4	12
42	Pilot Study on the Use of DNA Priming Immunization to Enhance <i>Y. pestis</i> LcrV-Specific B Cell Responses Elicited by a Recombinant LcrV Protein Vaccine. <i>Vaccines</i> , 2014, 2, 36-48.	4.4	10
43	Reduced MyD88 dependency of ISCOMATRIX <sup>®</sup> adjuvant in a DNA prime-protein boost HIV vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 1078-1090.	3.3	10
44	Cross reactivity of serum antibody responses elicited by DNA vaccines expressing HA antigens from H1N1 subtype influenza vaccines in the past 30 years. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 2049-2059.	3.3	9
45	Vaccine focusing to cross-subtype HIV-1 gp120 variable loop epitopes. <i>Vaccine</i> , 2014, 32, 4916-4924.	3.8	9
46	Antigen engineering can play a critical role in the protective immunity elicited by <i>Yersinia pestis</i> DNA vaccines. <i>Vaccine</i> , 2010, 28, 2011-2019.	3.8	8
47	Non-neutralizing antibodies targeting the immunogenic regions of HIV-1 envelope reduce mucosal infection and virus burden in humanized mice. <i>PLoS Pathogens</i> , 2022, 18, e1010183.	4.7	8
48	Screening of primary gp120 immunogens to formulate the next generation polyvalent DNA prime-protein boost HIV-1 vaccines. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2996-3009.	3.3	7
49	Structural Comparison of Human Anti-HIV-1 gp120 V3 Monoclonal Antibodies of the Same Gene Usage Induced by Vaccination and Chronic Infection. <i>Journal of Virology</i> , 2018, 92, .	3.4	7
50	DNA priming immunization is more effective than recombinant protein vaccine in eliciting antigen-specific B cell responses. <i>Emerging Microbes and Infections</i> , 2021, 10, 833-841.	6.5	6
51	Using DNA Immunization to Elicit Monoclonal Antibodies in Mice, Rabbits, and Humans. <i>Human Gene Therapy</i> , 2018, 29, 997-1003.	2.7	4
52	Pilot study on the immunogenicity of paired Env immunogens from mother-to-child transmitted HIV-1 isolates. <i>Human Vaccines and Immunotherapeutics</i> , 2012, 8, 1638-1647.	3.3	2
53	The values and limitations of mathematical modelling to COVID-19 in the world: a follow up report. <i>Emerging Microbes and Infections</i> , 2020, 9, 2465-2473.	6.5	2
54	Broadly binding and functional antibodies and persisting memory B cells elicited by HIV vaccine PDPHV. <i>Npj Vaccines</i> , 2022, 7, 18.	6.0	2

#	ARTICLE	IF	CITATIONS
55	The dynamics of immunoglobulin V-gene usage and clonotype expansion in mice after prime and boost immunizations as analyzed by NGS. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2987-2995.	3.3	1
56	Topology Influences V2 Epitope Focusing. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A193-A193.	1.1	0
57	A Novel Trimeric V1V2-Scaffold Immunogen Induces V2q-Specific Antibody Responses. <i>AIDS Research and Human Retroviruses</i> , 2014, 30, A121-A121.	1.1	0